Open AccessContinuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial
Author(s) -
Morihisa Hirota,
Tooru Shimosegawa,
Katsuya Kitamura,
Kazunori Takeda,
Yoshifumi Takeyama,
Toshihiko Mayumi,
Tetsuhide Ito,
Mamoru Takenaka,
Eisuke Iwasaki,
Hirotaka Sawano,
Etsuji Ishida,
Shin Miura,
Atsushi Masamune,
Yousuke Nakai,
Akira Mitoro,
Hiroyuki Maguchi,
Kenji Kimura,
Tsuyoshi Sanuki,
Tetsuya Ito,
Hiroki Haradome,
Kazuto Kozaka,
Toshifumi Gabata,
Keisuke Kataoka,
Masahiko Hirota,
Shuji Isaji,
Ryohji Nakamura,
Koki Yamagiwa,
Chie Kayaba,
Koji Ikeda
Publication year - 2019
Publication title -
journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.33
H-Index - 114
eISSN - 1435-5922
pISSN - 0944-1174
DOI - 10.1007/s00535-019-01644-z
Subject(s) - medicine , acute pancreatitis , context (archaeology) , adverse effect , pancreatitis , analgesic , randomized controlled trial , clinical endpoint , pancreas , hepatology , gastroenterology , anesthesia , paleontology , biology
Continuous regional arterial infusion (CRAI) of protease inhibitor nafamostat mesilate (NM) is used in the context of predicted severe acute pancreatitis (SAP) to prevent the development of pancreatic necrosis. Although this therapy is well known in Japan, its efficacy and safety remain unclear.